首页> 美国卫生研究院文献>Neuro-oncology Advances >IM-01 PI3K GAMMA INHIBITOR FOR OVERCOMING TREATMENT RESISTANCE IN COMBINATION THERAPY OF TEMOZOLOMIDE AND ANTI-PDL1 ANTIBODY FOR GLIOBLASTOMA PATIENTS
【2h】

IM-01 PI3K GAMMA INHIBITOR FOR OVERCOMING TREATMENT RESISTANCE IN COMBINATION THERAPY OF TEMOZOLOMIDE AND ANTI-PDL1 ANTIBODY FOR GLIOBLASTOMA PATIENTS

机译:IM-01 PI3Kγ抑制剂在胶质母细胞瘤患者联合应用替莫唑胺和抗-PDL1抗体治疗中克服抗药性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Multidisciplinary therapies including immunotherapy in glioblastoma (GBM) patients often cause long survivor, while early relapse of GBM still remains. We should find factors associated with the immunotherapy-resistance for overcoming it. We previously reported that the infiltration of PD-1 positive cells and M2 macrophages (M2M&phi) increased in recurrent specimens compared to the initial specimens of GBMs treated with chemo-radiotherapy and autologous formalin-fixed tumor vaccine. Here we evaluate whether combination of novel immunotherapies, anti-PD-L1 antibody and M2M&phi inhibitor (IPI-549) inhibits growth of temozolomide (TMZ)-treated glioma cells rather than monotherapy.
机译:胶质母细胞瘤(GBM)患者的包括免疫疗法在内的多学科疗法通常会导致长期存活,而GBM的早期复发仍然存在。我们应该找到与免疫治疗抵抗相关的因素来克服它。我们先前曾报道,与经化学放射疗法和自体福尔马林固定肿瘤疫苗治疗的GBM初始标本相比,复发标本中PD-1阳性细胞和M2巨噬细胞(M2M&phi)的浸润增加。在这里,我们评估了新型免疫疗法,抗PD-L1抗体和M2M&phi抑制剂(IPI-549)的组合是否抑制了替莫唑胺(TMZ)处理的神经胶质瘤细胞的生长,而不是单一治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号